Paul is President & CSO of Aleta Biotherapeutics and Founder & Principal of Sugarcone Biotech LLC. Paul's industry expertise covers bench to clinical trial development of diverse therapeutics for oncology, autoimmunity, inflammation and fibrosis (Repligen and Biogen). Since 2012 he has been involved in the genesis of novel biotechnology companies, most recently as co-founder of Aleta. Aleta Biotherapeutics develops transformative technologies to advance adoptive cellular therapies for the treatment of diverse cancers. Paul has authored numerous publications and patents, and recently served as editor for the review volume Novel Immunotherapeutic Approaches to the Treatment of Cancer.